Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Related Clinical Trial
A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals COPD Exacerbation Blood and Urine Biomarkers Study Alpha-1 Carrier Genomics Study Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype Study of ARO-AAT in Normal Adult Volunteers Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry Respreeza® Self-administration and Learning Program (AmAREtTI Study) Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Environment Effect on Six-Minute Walk Test Performance Alpha-1 Foundation DNA and Tissue Bank Alpha1-antitrypsin Deficiency Registry Alpha-1 Research Registry Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency Alpha-1 Coded Testing(ACT) Study Long-Term Follow-up Study of ADVM-043 Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation” EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency Alpha-1 Foundation Research Registry Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD A Study of DCR-A1AT in Healthy Adult Volunteers and Patients With A1ATD-Associated Liver Disease Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor) Aralast alpha1-proteinase Inhibitor Surveillance Study Pharmacokinetic Study of ARALAST (Human Alpha1- PI) The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Brief Title

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Official Title

Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency

Brief Summary

      The ADVANCE study is being conducted by Adverum Biotechnologies, Inc. as an open-label,
      multicenter, dose-escalation study in order to assess the safety and protein expression of
      ADVM-043 following a single intravenous or intrapleural administration.
    

Detailed Description

      Alpha-1 Antitrypsin (A1AT) is a major inhibitor of serine proteases and plays an important
      role in the lung as an inhibitor of neutrophil elastase. A1AT deficiency is associated with
      decreases in plasma A1AT levels and is associated with an increased risk for developing
      asthma, emphysema/COPD, and bronchiectasis. Much of the lung damage is thought to be caused
      by proteolytic damage from neutrophil elastase and other proteases.

      ADVM-043 is an investigational gene therapy product (serotype AAVrh.10 vector) expressing
      human A1AT that is intended to deliver a functional gene to the liver of patients with A1AT
      deficiency. Study ADVM-043-01 will study up to 4 dose levels in up to 20 patients and assess
      the hypothesis that a single administration of an AAV vector expressing the human M-type A1AT
      (i.e., ADVM-043) to patients with A1AT deficiency is safe and results in persistent
      therapeutic levels of A1AT in blood and alveolar epithelial lining fluid (epithelial lining
      fluid is only to be collected in subjects who are dosed intrapleurally). The primary endpoint
      is safety, and changes in plasma A1AT levels at multiple time points up to 52 weeks after
      dosing. A prophylactic tapering corticosteroid regimen will be used to protect against
      potential vector induced transaminitis. Subjects will be followed for up to 52 weeks after
      dosing. Safety and efficacy data from the IV cohorts will be considered when determining
      whether to proceed to intrapleural administration. After completion of this study, subjects
      will be asked to enroll in a Long Term Follow Up study.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Number and proportion of subjects experiencing adverse events

Secondary Outcome

 Changes in plasma concentrations of M-specific A1AT up to 52 weeks

Condition

Alpha 1-Antitrypsin Deficiency

Intervention

ADVM-043

Study Arms / Comparison Groups

 Part A: Dose 1
Description:  ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Genetic

Estimated Enrollment

6

Start Date

November 28, 2017

Completion Date

August 29, 2019

Primary Completion Date

August 29, 2019

Eligibility Criteria

        Key Inclusion Criteria:

          -  Capable of providing informed consent

          -  Alpha1AT genotype of ZZ or Z Null

          -  Males and females 18 years and older

          -  Ongoing treatment with A1AT augmentation is not required, however any subject
             receiving A1AT augmentation therapy must be willing to washout. Washout is defined as
             at least 8 weeks between last augmentation therapy and pre-treatment plasma A1AT level

          -  Willing to remain off PAT for at least 3 months following treatment

          -  Body mass index 18 to 35 kg/m2

          -  Fertile men and women of childbearing potential must agree to use barrier
             contraception for 3 months after treatment

        Key Exclusion Criteria:

          -  FEV1 <35 percent of predicted value at the Screening visit

          -  Receiving systemic corticosteroids or other immunosuppressive medications

          -  Immunodeficiency disease or evidence of active infection of any type, including human
             immunodeficiency virus

          -  Abnormal liver function tests

          -  Organ transplant recipient or awaiting transplantation

          -  Participation in another current or previous gene transfer study

          -  AAVrh.10 neutralizing antibody titer ≥ 1:5

          -  Female who is pregnant or lactating

          -  History of alcohol or drug abuse within the past 5 years

          -  Any history of allergies that may prohibit study-specific investigations

          -  Receiving an investigational medicinal product or participating in another
             investigational study within 3 months prior to consent

          -  Cigarette smoking, or any other tobacco use, e-cigarettes or other recreational
             inhalant within 1 year of the Screening Visit
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Charlton Strange, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02168686

Organization ID

ADVM-043-01


Responsible Party

Sponsor

Study Sponsor

Adverum Biotechnologies, Inc.


Study Sponsor

Charlton Strange, MD, Principal Investigator, Medical University of South Carolina, Charleston, SC, USA


Verification Date

January 2020